The American pharmaceutical company Bristol Myers Squibb announced on Sunday the acquisition, for $4.8 billion, of the Mirati Therapeutics laboratory, specializing in cancer treatments. “Bristol Myers Squibb and Mirati Therapeutics announced today that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Mirati for $58.00 per share in cash, for a total value of $4.8 billion dollars,” Bristol Myers Squibb said in a statement. Added to this is a guaranteed certificate of value (CVG), which could bring Mirati shareholders a potential additional value of $12 per share, or up to an additional $1 billion in total.
“The transaction was unanimously approved by the boards of directors of Bristol Myers Squibb and Mirati,” details the press release. “Mirati’s assets (…) represent an attractive opportunity to grow Bristol Myers Squibb’s oncology franchise. Through this acquisition, Bristol Myers Squibb will add Krazati, an important lung cancer drug, to its commercial portfolio,” explains the buyer.
“With several targeted oncology assets, including Krazati, Mirati represents another important step in our efforts to grow our diversified oncology portfolio and further strengthen Bristol Myers Squibb for the second half of the decade and beyond,” said further commented Chris Boerner, executive vice president of Bristol Myers Squibb.
